There is something special about PAINWeek beyond the obvious Vegas setting and the usual conference buzz of caffeinated colleagues sprinting from session to session, having hallwa ...
Aggregate OOP burden for generics exceeds brands due to utilization intensity, especially among Medicare beneficiaries with higher generic fill counts and near-parity annual OOP spending versus brands ...
Nirmatrelvir-ritonavir (Paxlovid) provided no measurable benefit for patients with long COVID, according to results from RECOVER-VITAL ( NCT05595369 ), a phase 2 randomized, double-blind, ...
Johnson & Johnson now requires comprehensive pharmacy/medical claims elements to be submitted to its 340B ESP platform, with suspension of all 340B pricing within five business days after repeated ...
Cox-adjusted analyses associated ≥1 year HRT use with reduced all-cause dementia (HR 0.90) and Alzheimer disease (HR 0.84), ...
National claims data (>104 million adults) showed higher unadjusted GLP-1 use in SMI, but adjustment for indications and ...
FDA approved 40-mg and 50-mg BID leniolisib for APDS in children 4–11 years weighing ≥27 kg, representing the first ...
AD109 produced statistically significant AHI improvement versus placebo at 26 weeks (treatment difference –4.0 events/hour; ...
The law of rhythm states, simply, that everything moves in a predictable cycle. Day follows night and seasons follow one ...
According to a study in The Lancet Microbe, genomic surveillance and broader vaccine targeting are significant factors in ...
mRNA technology predates COVID-19 by more than a decade, and a protein-based alternative exists for patients who remain ...
Advanced respiratory support during acute hospitalization demonstrated the strongest pooled association with post-COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results